[11] [12] Other key factors include: Dose level : Higher doses (e.g., 12 mg in trial protocols) produced greater weight loss than lower doses, though they were also associated with a higher incidence of gastrointestinal side effects
But so many people carry on taking them, sometimes for years, destroying their digestive tract and causing many more problems than they originally had
While these agents show great therapeutic efficacy in improving body weight and glycemic control, their use in developing organisms raises concerns about pleiotropic effects and impairment in developmental plasticity, requiring integrative approaches and cautious evaluation
Overall, we think this is an acceptable profile & orfo[rglipron] 36 mg generally looks in line vs Wegovy 2.4 mg/oral sema[glutide] 50 mg, Akash Tewari, global head of biopharmaceutical research with Jefferies, wrote in a research note
Several CSV queries ask about adding CJC-1295 to make a triple blend
Q.GLP-1 A